Haleon
Haleon plc (FTSE 100: HLN) is listed on the London Stock Exchange, it is a British multinational consumer healthcare company and a global leader in over the counter medicines.
Haleon was spun out of GSK and established on the 18th July 2022, it is the largest consumer healthcare business in the world.
The business is owned by GSK (13%) & Pfizer (32%) and the rest making up institutional funds and private investors.
Haleon’s purpose is to “improve the everyday health of everyone, everywhere”.
The company’s products are divided into 5 categories:
- Pain Relief
- Respiratory Health
- Digestive Health
- Oral Health
- Vitamins, minerals & supplements (VMS)
Haleon Brands
There are 5 power categories, then within each, there are local strategic brands.
- Pain Relief – Advil, Excedrin, Fenbid, Panadol, Voltaren,
- Respiratory Health – Contac, Flonase, Otrivin, Theraflu.
- Digestive Health – Eno, Fenistil, Nicolette, Nexium, Tums.
- Oral Health – Aquafresh, biotene, Parodontax, Polident, Sensodyne.
- Vitamins, minerals & supplements (VMS) – Caltrate, Centrum, Emergen-C
Following the spin out from GSK the business was carrying quite an amount of debt, so in the early stages the business did not pay or distribute any dividends.
Haleon’s initial intention to pay down debt has been well executed, enabling the business to start distributing bi-annual dividends from 2022.
At the proposed business spin-out we were entitled to be included in the newly formed Haleon shares through holding our original 100 GSK shares.
Each shareholder would stand to gain one share of HLN for every held GSK share.
The reason we opted for the GSK share split was after reading and digesting all the information about the new business, and by understanding where and how it would be positioned on the global stage did we choose to proceed.
We perceive Haleon plc to be a well positioned business within the future healthcare space, where it should be able to add value to the existing portfolio of brands whilst growing both reoccurring revenues and income.
Being aware of its current brands, size, together with its ability to build on existing and add new brands and products, I foresee Haleon being a popular dividend stock in portfolios of the future.
Haleon Dividends
As Haleon is a newly spun out business, then the dividend history is somewhat limited to just three years:
2025 £0.0710 pence
2024 £0.0660 pence
2023 £0.0600 pence
2022 £0.0.24 pence
Projections for the final year end distribution of a dividend will be announced early in 2026, subject to financials, debt obligations and repayments.
A interim dividend for 2026 was announced at £0.0240 pence per share, and was paid on 17/09/26, going ex-dividend 13/08/26)
We look forward to seeing Haleon growing the future dividends, subject to reducing the debt and providing sales continue to grow.
P/E: 18.26 (17/09/26)
Dividend Yield: 2.09% (14/05/26)
Total income received to date is just £24.50
Further dividend analysis can be viewed in the file below:
Alternatively, click on the link here to see how the Haleon payments contributes to the total 2025 income.
HLN
Important Disclaimer:
The content on this website is published solely for educational, research, and informational purposes and reflects personal opinion and portfolio tracking. It does not constitute personal financial, investment, or tax advice, nor is it an offer or solicitation to buy or sell any security.
The value of investments and the income derived from them can fall as well as rise, and you may not recover the full amount originally invested. Past performance and dividend yields are not reliable indicators of future results.
If you are uncertain about the suitability of any investment mentioned, please consult an independent financial adviser authorised and regulated by the Financial Conduct Authority (FCA).
